At lower end of guidance $20m revenue at say 20% net profit...

At lower end of guidance $20m revenue at say 20% net profit margin = $4m EBIT, and around $2.8m NPAT.
404m shares so 0.69 cents per share, puts this at a P/E of 60.
At higher end of guidance $50m revenue, $10m EBIT, $7m NPAT, 1.7c/share, P/E of 25.

Float price would seem fair value, and current price overbought, unless there's significant growth potential for beyond 12 months.

I would say the flipside is likely and covid-19 may not be a huge problem beyond the pandemic phase and they are back to $5-8m revenue from HIV test kits in 2-3 years time.